NICE backpedals on decision to limit access to Roche's Tarceva
This article was originally published in Scrip
Executive Summary
NICE has made a U-turn on its decision to restrict the use of Roche's Tarceva (erlotinib) in second-line non-small cell lung cancer (NSCLC).